Pembrolizumab berahyaluronidase alfa vs Sasanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Sasanlimab
Developed by Pfizer
NCT04181788 · Phase 1/2 · completed
Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.
Reported efficacy
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)
Result source: NCT04181788
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pembrolizumab berahyaluronidase alfa | Sasanlimab |
|---|---|---|
| PFS, median | —Trial running · NCT05722015 | —Trial running · NCT06218069 |
| OS, median | —Trial running · NCT05722015 | 14.7bNCT025732591 other result
|
| ORR | 64.3% vs 18.2%vs PembrolizumabNCT06212752 | 16.4%bNCT025732593 other results
|
| Duration of response, median | —Trial running · NCT05722015 | —Trial running · NCT06218069 |
PFS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sasanlimab
- —Trial running · NCT06218069
OS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sasanlimab
- 14.7bNCT02573259
1 other result
- 10.9 NCT02573259
ORR
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
- Sasanlimab
- 16.4%bNCT02573259
3 other results
- 18.4% NCT02573259
- 19.4% NCT02573259
- 21.1% NCT02573259
Duration of response, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sasanlimab
- —Trial running · NCT06218069
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Sasanlimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab berahyaluronidase alfa | Sasanlimab |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | n/a: no completion milestone600 mg SC Q6Wb NCT04181788 · Phase 1/2 show 12 more resultsn/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 86.7%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.3%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 87.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.7%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 75%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 100%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 16.7%600 mg SC Q6Wb NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 3.8%600 mg SC Q6W NCT04181788 · Phase 1/2 0%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 2.4%300 mg SC Q4W NCT04181788 · Phase 1/2 —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 39%a NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 0%600 mg SC Q6Wb NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 16.3%600 mg SC Q6W NCT04181788 · Phase 1/2 25%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 39%300 mg SC Q4W NCT04181788 · Phase 1/2 20%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 26.5%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 34.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 42.9%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 600 mg SC Q6Wb pruritus 50% alanine aminotransferase increased 16.7% alopecia 16.7% NCT04181788 · Phase 1/2 show 12 more results600 mg SC Q6W anaemia 50% blood glucose increased 33.3% blood bilirubin increased 25% NCT04181788 · Phase 1/2 300 mg SC Q4W alanine aminotransferase increased 25% anaemia 25% aspartate aminotransferase increased 25% NCT04181788 · Phase 1/2 300 mg SC decreased appetite 46.7% nausea 40% dyspnoea 33.3% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 19.1% dyspnoea 14.7% decreased appetite 13.2% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 31.6% asthenia 15.8% back pain 15.8% NCT02573259 · Phase 1 · registry result, not featured evidence 10 mg/kg IV generalised oedema 57.1% constipation 42.9% aspartate aminotransferase increased 28.6% NCT02573259 · Phase 1 · registry result, not featured evidence 3 mg/kg IV generalised oedema 50% arthralgia 37.5% blood thyroid stimulating hormone increased 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 1 mg/kg IV constipation 50% decreased appetite 37.5% generalised oedema 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 0.5 mg/kg IV back pain 100% blood creatinine increased 100% constipation 100% NCT02573259 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab berahyaluronidase alfa
Sasanlimab
show 3 more results
show 9 more results
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Sasanlimab's landscape